4.7 Review

Current and future direction in treatment of HPV-related cervical disease

Journal

JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 100, Issue 6, Pages 829-845

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00109-022-02199-y

Keywords

Human papillomavirus; Therapeutic vaccine; Clinical trial; Cervical disease; CRISPR; Cas

Ask authors/readers for more resources

This review provides a detailed overview of the current treatment options for HPV-related cervical precancerous and cancerous diseases, including therapeutic vaccines and the use of genome-editing CRISPR/Cas system. Although the development of vaccines has been slow, recent trials have shown promising results.
Human papillomavirus (HPV) is the most common sexually transmitted virus in the world. About 70% of cervical cancers are caused by the most oncogenic HPV genotypes of 16 and 18. Since available prophylactic vaccines do not induce immunity in those with established HPV infections, the development of therapeutic HPV vaccines using E6 and E7 oncogenes, or both as the target antigens remains essential. Also, knocking out the E6 and E7 oncogenes in host genome by genome-editing CRISPR/Cas system can result in tumor growth suppression. These methods have shown promising results in both preclinical and clinical trials and can be used for controlling the progression of HPV-related cervical diseases. This comprehensive review will detail the current treatment of HPV-related cervical precancerous and cancerous diseases. We also reviewed the future direction of treatment including different kinds of therapeutic methods and vaccines, genome-editing CRISPR/Cas system being studied in clinical trials. Although the progress in the development of therapeutic HPV vaccine has been slow, encouraging results from recent trials showed vaccine-induced regression in high-grade CIN lesions. CRISPR/Cas genome-editing system is also a promising strategy for HPV cancer therapy. However, its safety and specificity need to be optimized before it is used in clinical setting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available